CIP2A and hepatocellular carcinoma: CIP2A has also been found to regulate PP2A expression [50,53], and given the fact PP2A was shown to affect bortezomib and erlotinib cytotoxicity in HCC cells [52], its reactivation could be a significant component against drug resistance.